Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, Leonhard SE, Verboon C, Huizinga R, Drenthen J, Arends S, Budde IK, Kleyweg RP, Kuitwaard K, van der Meulen MFG, Samijn JPA, Vermeij FH, Kuks JBM, van Dijk GW, Wirtz PW, Eftimov F, van der Kooi AJ, Garssen MPJ, Gijsbers CJ, de Rijk MC, Visser LH, Blom RJ, Linssen WHJP, van der Kooi EL, Verschuuren JJGM, van Koningsveld R, Dieks RJG, Gilhuis HJ, Jellema K, van der Ree TC, Bienfait HME, Faber CG, Lovenich H, van Engelen BGM, Groen RJ, Merkies ISJ, van Oosten BW, van der Pol WL, van der Meulen WDM, Badrising UA, Stevens M, Breukelman AJ, Zwetsloot CP, van der Graaff MM, Wohlgemuth M, Hughes RAC, Cornblath DR, van Doorn PA; Dutch GBS Study Group. Walgaard C, et al. Among authors: van der meulen wdm. Lancet Neurol. 2021 Apr;20(4):275-283. doi: 10.1016/S1474-4422(20)30494-4. Epub 2021 Mar 17. Lancet Neurol. 2021. PMID: 33743237 Clinical Trial.
Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study.
Luijten LWG, Leonhard SE, van der Eijk AA, Doets AY, Appeltshauser L, Arends S, Attarian S, Benedetti L, Briani C, Casasnovas C, Castellani F, Dardiotis E, Echaniz-Laguna A, Garssen MPJ, Harbo T, Huizinga R, Humm AM, Jellema K, van der Kooi AJ, Kuitwaard K, Kuntzer T, Kusunoki S, Lascano AM, Martinez-Hernandez E, Rinaldi S, Samijn JPA, Scheidegger O, Tsouni P, Vicino A, Visser LH, Walgaard C, Wang Y, Wirtz PW, Ripellino P, Jacobs BC; IGOS consortium. Luijten LWG, et al. Brain. 2021 Dec 16;144(11):3392-3404. doi: 10.1093/brain/awab279. Brain. 2021. PMID: 34553216 Free PMC article.
Presentation outside office hours does not negatively influence treatment times for reperfusion therapy for acute ischemic stroke.
Groot AE, de Bruin H, Nguyen TTM, Kappelhof M, de Beer F, Visser MC, Zwetsloot CP, Halkes PHA, de Kruijk J, van der Meulen WDM, van der Ree TC, Kwa VIH, van Schaik SM, Hani L, van den Berg R, Sprengers MES, Roosendaal SD, Emmer BJ, Nederkoorn PJ, Majoie CBLM, Roos YBWEM, Coutinho JM. Groot AE, et al. Among authors: van der meulen wdm. J Neurol. 2021 Jan;268(1):133-139. doi: 10.1007/s00415-020-10106-z. Epub 2020 Jul 31. J Neurol. 2021. PMID: 32737653 Free PMC article.
Association between i.v. thrombolysis volume and door-to-needle times in acute ischemic stroke.
Groot AE, van Schaik IN, Visser MC, Nederkoorn PJ, Limburg M, Aramideh M, de Beer F, Zwetsloot CP, Halkes P, de Kruijk J, Kruyt ND, van der Meulen W, Spaander F, van der Ree T, Kwa VI, Van den Berg-Vos RM, Roos YB, Coutinho JM. Groot AE, et al. J Neurol. 2016 Apr;263(4):807-13. doi: 10.1007/s00415-016-8076-5. Epub 2016 Mar 5. J Neurol. 2016. PMID: 26946499 Free PMC article.
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, Leonhard SE, Verboon C, Huizinga R, Drenthen J, Arends S, Budde IK, Kleyweg RP, Kuitwaard K, van der Meulen MFG, Samijn JPA, Vermeij FH, Kuks JBM, van Dijk GW, Wirtz PW, Eftimov F, van der Kooi AJ, Garssen MPJ, Gijsbers CJ, de Rijk MC, Visser LH, Blom RJ, Linssen WHJP, van der Kooi EL, Verschuuren JJGM, van Koningsveld R, Dieks RJG, Gilhuis HJ, Jellema K, van der Ree TC, Bienfait HME, Faber CG, Lovenich H, van Engelen BGM, Groen RJ, Merkies ISJ, van Oosten BW, van der Pol WL, van der Meulen WDM, Badrising UA, Stevens M, Breukelman AJ, Zwetsloot CP, van der Graaff MM, Wohlgemuth M, Hughes RAC, Cornblath DR, van Doorn PA; Dutch GBS Study Group. Walgaard C, et al. Among authors: van der meulen wdm. Lancet Neurol. 2021 Apr;20(4):275-283. doi: 10.1016/S1474-4422(20)30494-4. Epub 2021 Mar 17. Lancet Neurol. 2021. PMID: 33743237 Clinical Trial.
Safety and efficacy of active blood-pressure reduction to the recommended thresholds for intravenous thrombolysis in patients with acute ischaemic stroke in the Netherlands (TRUTH): a prospective, observational, cluster-based, parallel-group study.
Zonneveld TP, Vermeer SE, van Zwet EW, Groot AED, Algra A, Aerden LAM, Alblas KCL, de Beer F, Brouwers PJAM, de Gans K, van Gemert HMA, van Ginneken BCAM, Grooters GS, Halkes PHA, van der Heijden-Montfroy TAMHG, Jellema K, de Jong SW, Lövenich-Ciccarello H, van der Meulen WDM, Peters EW, van der Ree TC, Remmers MJM, Richard E, Rovers JMP, Saxena R, van Schaik SM, Schonewille WJ, Schreuder TAHCML, de Schryver ELLM, Schuiling WJ, Spaander FH, van Tuijl JH, Visser MC, Zinkstok SM, Zock E, Dippel DWJ, Kappelle LJ, van Oostenbrugge RJ, Roos YBWEM, Vermeij FH, Wermer MJH, van der Worp HB, Nederkoorn PJ, Kruyt ND. Zonneveld TP, et al. Among authors: van der meulen wdm. Lancet Neurol. 2024 May 15:S1474-4422(24)00177-7. doi: 10.1016/S1474-4422(24)00177-7. Online ahead of print. Lancet Neurol. 2024. PMID: 38763149
13 results